Issues
-
Cover Image
Cover Image
About the Cover
Little is known of the role of IL17A or Th17 cells in solid tumors. Non–small cell lung cancer (NSCLC) is a solid tumor driven by multiple oncogenic mutations. Mice with deletions in their airway cells of the Pten and Smad4 genes, independent of Kras mutations, recapitulate NSCLC in humans, including histologic features and metastatic propensities of two subtypes of NSCLC. You et al. found that if these mice also lacked the cytokine IL17A, tumors developed more rapidly and were more metastatic. Comparison of the antitumor responses in mice with and without Il17a showed that the successful antitumor responses were mediated by T cells expressing IL17A. Read more starting on page 645 of this issue. Original image from Fig. 4. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Cancer Immunology Miniature
Priority Brief
Research Articles
IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.